Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cefepime/AAI101 PK in ELF and Plasma
NCT03680378Phase 1Completed
- Sponsor
- Allecra Therapeutics
- Start
- Jul 2017
- Primary completion
- Apr 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of enmetazobactam in bacterial infection, sponsored by Allecra Therapeutics. Primary endpoint: Maximum concentration of cefepime and AAI101 in the lung at 8 hours. Started Jul 2017; status: completed.
02
Drugs
enmetazobactam
03
Conditions
bacterial infection
Beyond the preview
Go deeper on NCT03680378.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03680378.